investors

eXoZymes Investor Presentation (April 2026)

Sat, 18 Apr 2026 01:46:54 GMT

NCT presentation by Damien Perriman, CCO

Fri, 03 Apr 2026 21:13:50 GMT

Nasdaq: Damien Perriman interview on NCT

Thu, 02 Apr 2026 17:31:33 GMT

CCO at eXoZymes, Damien Perriman, interviewed at Nasdaq around our NCT project:

"We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine."

EXOZ Investor Update - Q4+2025 (March 31. 2026)

Wed, 01 Apr 2026 22:26:12 GMT

Interview: Cayman Chemical validates eXoZymes' technology and scalability

Wed, 18 Mar 2026 13:59:35 GMT

Using eXoZymes' tech transfer package, Cayman Chemical advanced the protocol from a one-liter setup to a 100-liter pilot run, operating the reaction, downstream processing, and analysis independently. During the run, the team encountered real-world conditions - including pH variation and precipitation - which often cause enzyme-based processes to fail. Despite this, the reaction continued to perform reliably and delivered strong results, ultimately producing more than 500 grams of pharma-grade N-trans-caffeoyltyramine (NCT) at 99.6% purity, a result that is difficult to obtain in biomanufacturing without extensive purification steps. Additionally, the 99% conversion of feedstock to end product highlights a level of efficiency that is challenging to achieve and maintain in traditional biomanufacturing.

For Cayman Chemical, the outcome stood out based on prior experience as highlighted by Patrick Westcott, Director of Catalog Chemistry Production at Cayman Chemical: “I’ve performed a lot of cell-based enzymatic biocatalysis over the years; it is a critical component of what we do at Cayman. One common aspect of this work is a drop in efficacy during scale-up. Anytime you move up in scale orders of magnitude, a process changes enough that it is considered a different process altogether.”

Westcott, continues, “During the experiment, from the first sample that we took the analysis showed over a 99% conversion rate. There was some concern because I thought that that maybe was a little bit too high. So, we decided to take a second sample to see if it maintained a similar conversion rate. And we were a little surprised to find out that we actually did achieve this 99% conversion in our first 100-fold scale up of their process. That was very much an aha moment for us!”

Rapid Scale-Up: Enzyme Breakthrough Achieved! (01)

Wed, 18 Mar 2026 13:59:23 GMT

One of the biggest challenges of conventional technologies is the long timelines to advance through scale-up.

In this particular instance, the lack of chromatography and of multi-stage synthesis meant that we actually were able to move from one liter scale to a hundred liter scale in a matter of a couple of days. When we reached the end of that and we had achieved this 99% conversion, I was really surprised and really pleased with the robustness of the enzyme.

Lou Basenese: CEO spotlights

Mon, 02 Mar 2026 22:23:59 GMT

Chief Scientific Officer, Tyler Korman, PhD

Fri, 14 Nov 2025 00:11:36 GMT

NCT: Damien on 4 grams of NCT with over 99% purity

Tue, 29 Jul 2025 13:40:25 GMT

🔬 Biomanufacturing breakthrough detailed: 4 grams of NCT produced at a 96% yield and with a purity higher than 99% 💥

Chief Commercial Officer at eXoZymes, Damien Perriman, states:

"The beauty of leading with NCT as our first push to market, is that the compound has already been self-affirmed in the market as generally recognized as safe (GRAS) for functional foods. Additionally, it has multiple potential applications across different verticals in prebiotics, dietary supplements, and pharmaceuticals. We’re ramping up NCT production scale 100X over the next six months to both deliver samples to our partners as well as prepare for tech transfer to GMP pilot scale production next year. We are ready to start partner discussions for kilogram demand in 2026 and beyond that - ton scale.”

📽️ Full story here: https://exozymes.com/blog/nct-breakthrough-purity

👉 Early access partnerships now open: https://exozymes.com/partners

NCT: From concept to gram-scale quantity in only 5 months

Tue, 22 Jul 2025 22:01:57 GMT

🚀 Biomanufacturing breakthrough: Using our AI-powered, cell-free exozyme platform, we’ve gone from concept to gram-scale NCT in only 5 months!

Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states,

"Going from the original proof-of-concept to lab scale validation, our goal was to make a first version of a biosolution that can produce at least one gram of NCT per batch, which we now have delivered on with an impressive 96% reaction yield. Not only does this biomanufacturing breakthrough prove the technical proficiency of our platform - but we have also accomplished this in only 5 months and with a limited budget. A timeline that’s unheard of in SynBio or anywhere, really.”

This isn’t just a milestone for NCT - it’s a validation of our 'powered by eXoZymes' biosolution platform that can unlock 100s of valuable natural products.

📽️ Full story here: https://exozymes.com/blog/nct-breakthrough-paul

👉 Early access partnerships now open: https://exozymes.com/partners

Slack Capital interview: Damien Perriman, CCO

Wed, 21 May 2025 21:58:47 GMT

Last week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our CCO, Damien Perriman, focuses on the commercialization of our platform.

Perriman states: "We're moving really quick, like things that I would expect a year to take, we're doing in weeks. That kind of blew my socks off and I started speaking to some of my colleagues, asking what if we could actually move a proof of concept so much faster than we did before? What does that mean for the type of partnerships that we could create? Or could we engage partners much sooner in the equation than we did before?"

Full interview is available here:

[link]

#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport

Slack Capital interview: Damien Perriman, CCO (teaser)

Wed, 21 May 2025 21:58:32 GMT

Full interview is available here:

https://exozymes.com/blog/slack-capital-cco

#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport

Slack Capital interview: Tyler Korman, VP of Research

Mon, 19 May 2025 00:26:44 GMT

This week, Slack Capital - an Australian investment research publication - has released an investment report on eXoZymes accompanied by multiple interviews with our management team. This interview with our co-founder and VP of Research, Tyler Korman, PhD, focuses on the science behind our platform.

Full interview is available here:

https://exozymes.com/blog/slack-capital-vpofresearch

#AI #biomanufacturing #nutraceuticals #enzymes #exozymes #investmentreport

eXoZymes launches subsidiary, NCTx, to unlock a promising compound for gut...

Tue, 06 May 2025 22:18:50 GMT

At the yearly SynBioBeta conference, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced the formation of ‘NCTx, LLC’ (NCTx), a purpose-built subsidiary company focused on the development and production of N-trans-caffeoyltyramine - a very rare, plant-derived compound with emerging relevance in the areas of metabolic health, gut integrity, and liver function.

Full story here: https://exozymes.com/blog/nctx-launch

AI transforming biotechnology: From form with AlphaFold to function with...

Mon, 28 Apr 2025 20:47:39 GMT

Co-founder and VP of Development at eXoZymes, Dr. Paul Opgenorth, states:

"The Large Language Models (LLMs) actually got to learn our vocabulary by breaking down the English language to its core constituents - the 26 letters of the alphabet. Then the LLM identifies patterns and stitches the letters together in order to coherently answer the questions we give it. Conversely, you can think of enzymes in the same way. Enzymes are made up of 20 amino acids and LLMs can make the same correlations between these amino acids to get to stable structures. We can use these stable structures to make better enzymes and even select for properties that would up-classify them to exozymes."

Full story:

https://exozymes.com/blog/alphafold-to-exozymes

#enzymes #exozymes #biomade #alphafold #proteinstructure

Introducing our new CCO: Damien Perriman

Wed, 02 Apr 2025 22:43:18 GMT

Our new Chief Commercial Officer, Damien Perriman, brings more than two decades of experience in successfully commercializing several biotechnologies, across areas such as nutrition, personal care, plastics, textiles, fragrances, performance fuels, and specialty chemicals. Before joining eXoZymes, Perriman most recently has served leading commercial roles at both Genomatica (Geno) and Gevo, while also serving as Chairman of the Board of Danish biotechnology startup Cellugy.

Fox Business interview with CEO Michael Heltzen

Thu, 13 Mar 2025 21:58:14 GMT

CNBC closing bell footage from Feb 19, 2025

Fri, 21 Feb 2025 18:33:16 GMT

Part of the coverage of eXoZymes’ closing bell ceremony on Feb 19, 2025 from CNBC.

Credit: CNBC & Nasdaq, Inc.

Nasdaq: The full eXoZymes closing bell ceremony from Feb 19, 2025

Thu, 20 Feb 2025 17:54:42 GMT

Nasdaq: eXoZymes CEO Michael Heltzen's closing bell speech

Thu, 20 Feb 2025 17:42:07 GMT

This Michael Heltzen's (CEO of eXoZymes) closing bell speech from February 19, 2025, when eXoZymes rang the closing bell at Nasdaq in New York.

CEO of eXoZymes, Michael Heltzen, states: "I want to bring the attention to that this is the beginning of a long journey. It's a thing where we are going to have to have partners and collaborators help out. This is not a technology breakthrough that we are going to keep to ourselves. We want to share it. We want to share it with all of the world. And with that, please come join us, help us, support us, at least follow us so we can have a conversation about how the future can be a more sustainable future while still having the good life."

Credit: Nasdaq, Inc.

Looking at the rest of 2025 - part 4 of a fireside chat about Invizyne

Tue, 11 Feb 2025 04:07:15 GMT

In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne Technologies’ CEO Michael Heltzen about the Invizyne’s plans for the rest of 2025.

“There is a rebranding effort coming up very soon where we will be basically not just introducing ourselves with a new name, but also with a new way of explaining exactly what it is we're doing as a company in a way that is easier to understand and why that has value. On top of that, we can't just look like everybody else when we are so fundamentally different. So we will make sure that both in communication, but also in look and feel that we make sure people can remember us and our value proposition.” said Heltzen.

Go To Market Strategy - part 3 of a fireside chat about Invizyne

Wed, 15 Jan 2025 23:19:49 GMT

In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne Technologies’ CEO Michael Heltzen about the Invizyne’s Go To Market strategy for 2025.

“All of this potential doesn't matter if we don't turn it into something that creates value. And getting to those first applications are the value inflection points that we're aiming for this year. So a systematic platform approach but with a focus on getting to market in the high valuable compounds / chemicals spaces first and then the extraordinary business opportunities that, for example, is the isobutanol and sustainable aviation fuel where we have a partner in the US government that wants to and needs to see that happen and therefore is willing to sponsor that whole area.” said Heltzen.

Stay tuned for Part 4 - “looking ath the rest of 2025”. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well!

Using AI for Enzyme Engineering - part 2 of a fireside chat about Invizyne

Tue, 07 Jan 2025 15:28:42 GMT

In this video - recorded on Dec 29, 2024 - MDB Capital Group’s Lou Basenese interviews Invizyne Technologies’ CEO Michael Heltzen about the core technology behind Invizyne's platform and how it's based on no less than four current Nobel Prizes in chemistry.

What’s more, while everyone is preoccupied with talking about AI in terms of Nvidia Corp.’s (#NVDA) impressive growth, the two discuss how AI is also dramatically impacting and accelerating Invizyne’s enzyme engineering capabilities.

“Why does this matter? It's a new generation of access to chemicals. A new way where we don't use oil as a starting point. What is chemistry? It's your good life. It's what you're wearing right now. It is the sofa behind you. It is the paint on your walls. It is the colors you see in all materials. It is also in your food and in your medicine, in the fragrance and the flavors that makes the good life,” said Heltzen.

Stay tuned for Part 3 about Invizyne’s Go-To-Market strategy. And please remember to follow Michael Heltzen and Invizyne to be sure to get all future updates as well!

Looking back at 2024 - part 1 of a fireside chat about Invizyne

Thu, 02 Jan 2025 22:21:05 GMT

In this video - recorded on Dec 29, 2024 - Lou Basenese interviews Michael Heltzen about going IPO and the current challenges in SynBio - and how Invizyne can alleviate them - among other interesting topics, including the introduction of a paradigm shift in biomanufacturing.

“What does our technology do? We build biosolutions. Humankind has built a lot of things based on petrochemicals or things we have taken from nature and made into chemicals. We can make a new generation of that by re-engineering enzymes, putting them in a bioreactor, and making them produce all kind of chemicals that turns into products - like drugs, nutraceuticals, and all the way out to industrial chemicals like biofuels.” – states Michael Heltzen

Please remember to follow Michael Heltzen and Invizyne, to be sure to get future updates as well!

Invizyne IPO comments by CEO Michael Heltzen

Mon, 11 Nov 2024 23:41:56 GMT

Today's Nasdaq IPO marks new era of biomanufacturing - pioneered by Invizyne's breakthrough cell-free platform

Co-founder of Invizyne and UCLA Professor Emeritus James Bowie, states, “We were frustrated with the limitations of working with enzymatic pathways inside cells, which made us wonder whether we could get rid of the cells altogether. I was lucky to have a team with enough talent and grit to actually make it work.”

Invizyne's CEO, Michael Heltzen, adds, "Today is an amazing day. That's one of those typical overnight successes that takes a decade to prepare for. We are from a perspective of IPOing, an early stage IPO. It means, this is in no way a celebration to exit and like 'it's over'. It's the exact the opposite: Today, we start the real journey on introducing the world to cell-free biomanufacturing!"

See the full interview below. Press releases available here:

https://www.invizyne.com/nasdaq-ipo

Invizyne is trading on Nasdaq under the ticker symbol "IZTC".

#biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech #nasdaq #IPO

Dr. Lalonde: From two years and 25 scientists to a few scientists for a few...

Thu, 08 Aug 2024 11:26:11 GMT

Dr. Lalonde: From two years and 25 scientists to a few scientists for a few months

"When I started out in 2004, that was the early days of enzyme engineering while we were still developing the tools at that point. One of the projects we worked on was Lipitor [...] I think it was $14 billion a year revenue. [...] The challenges with those kind of programs was that it was two years and 25 scientists to do one enzyme. It was a big, big spend. Now, with Invizyne, it's a few scientists for few months that can do an enzyme. So it'really a couple of orders of magnitude reduction in the amount of R&D because of the the tools have gotten so much better. [...] All these things have brought down the cost of R&D and increased the target." ~ states synthetic biology key opinion leader, Dr. James J. Lalonde, in an interview.

You can see the full interview here:
Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024)

#biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech

Dr. Lalonde: Invizyne [...] helps the sustainability of this planet

Thu, 08 Aug 2024 11:26:03 GMT

"Invizyne is taking what nature has done and [...] putting things in a manufacturing format so we can make materials at low cost and really help the sustainability of this planet." ~ states synthetic biology key opinion leader, Dr. James J. Lalonde, in an interview.

You can see the full interview here:
Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024)

#biomanufacturing #nextgenbiomanufacturing #cellfree #enzymes #biochemistry #biochemicals #synbio #syntheticbiology #synbiobeta #biosynthesis #simplepath #scalablebiochemistry #scalable #energytransition #endocannabinoids #cannabinoids #sustainableaviationfuel #SAF #greentech #cleantech

Commercializing Invizyne’s cell-free platform - fireside chat

Tue, 30 Jul 2024 00:59:46 GMT

Commercializing Invizyne’s cell-free platform - fireside chat withZachary Karl, PhD, Vice President of Business Development at Invizyne - and - Lou Basenese President & Chief Market Strategist at MDB Capital

Invizyne IPO - KOL Call with Dr. James J. Lalonde (July 17, 2024)

Mon, 22 Jul 2024 21:15:46 GMT

MDB Capital President and Chief Market Strategist Lou Basenese talks with Dr. James J. Lalonde, a recognized leader in the field of synthetic biology and Invizyne board member on July 17, 2024.

Invizyne is a leading designer of cell-free, enzyme-based biomanufacturing systems to produce commercially important molecules and chemicals for everyday life, which recently filed a registration statement for an initial public offering (IPO). MDB Capital is acting as the sole underwriter for the offering.

The information contained in this presentation has been prepared to assist interested parties in making their own evaluation of the investment opportunity related to the Company and does not purport to be all-inclusive or to contain all of the information that a prospective investor may desire. In all cases, interested parties should conduct their own investigation and analysis of the data set forth in this presentation and the registration statement for the offering. The Company has not assumed any responsibility for independent verification of any of the forward-looking information contained in this presentation or the related registration statement, including projections and future events and assumptions on which the projections and future events are based. None of the Company or their respective affiliates and representatives makes any representation or warranty (expressed or implied) as to the accuracy or completeness of the forward-looking information contained in this presentation and the related registration statement. Those parties or entities expressly disclaim any and all liability based on or relating to any representations or warranties (expressed or implied) contained in, or errors or omission from, this presentation and the related registration statement or based on or relating to the recipient’s use or the use by any of its affiliates or representatives of this presentation or the related the registration statement or any other written or oral communications transmitted to the recipient or any of its affiliates or representatives in the course of its investment evaluation related to this investment opportunity.

The offering will be made only by means of a prospectus forming a part of the registration statement on Form S-1 relating to these securities that has been filed by the Company with the U.S. Securities and Exchange Commission but has not become effective. The common stock of Invizyne Technologies, Inc. may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. For additional information on Invizyne Technologies, Inc. and the offering, please review the current registration statement on Form S-1 (# 333-276987) that can be found at SEC.gov EDGAR Entity Landing Page: sec.gov/edgar/search/#/ciks=0002010788. A prospectus may also be obtained from MDB Capital by writing to MDB Capital, Prospectus Department, 14135 Midway Road, Suite G-150, Addison, Texas 75001 or emailing community@mdb.com.

Securities offered by the Company are highly speculative. Investing in the shares of common stock of the Company involves significant risks. The investment is suitable only for persons who can afford to lose their entire investment. Furthermore, investors must understand that an investment in the Company common stock could be illiquid for an indefinite period of time.

Prior to this offering, there has been no public market for the shares of common stock of the Company. The Company has applied to list its shares of common stock on the Nasdaq Capital Market, sometimes referred to as “Nasdaq.” The listing will not be approved until the time of the offering. No assurance can be given that the application will be approved or that an active trading market for the shares of common stock will develop. The Company will not consummate and close this offering without a listing approval letter from Nasdaq. If the Company does not receive a Nasdaq listing approval, they will terminate the offering.

MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.

Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures:
mdb.com/disclosures.

NOTICE: Securities trading, account management, and investment banking services are offered by MDB Capital, a registered broker-dealer and member of FINRA and SIPC. Unless clearly stated, nothing herein shall be construed to be an offer to sell, nor a solicitation of an offer to buy, any financial product.

Invizyne presented by Michael Heltzen & Tyler Korman

Mon, 01 Jul 2024 22:55:28 GMT

In this video, CEO of Invizyne, Michael Heltzen - and VP of Research, Tyler Korman, PhD - presents Invizyne.

MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.

Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures:
mdb.com/disclosures.

Invizyne presented by Chris Marlett

Thu, 13 Jun 2024 22:24:57 GMT

In this video, CEO of MDB Capital Holdings, Chris Marlett, presents Invizyne.

MDB Capital is required to provide you with certain disclosures and informational resources pertaining to your account and investment activity.

Please follow the link below to review MDB Capital’s Form CRS and additional relevant disclosures:
mdb.com/disclosures.